Consequently, the selective CHK1 inhibitor MK-8776 has entered clinical trials for the treatment of certain solid tumors and acute leukemia16,17; however, it remains unclear how CHK1 inhibition by MK-8776 triggers chemosensitization in bladder cancer cells. The gene discussed is CHEK1; the disease is urinary bladder carcinoma.